Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection

Abstract

Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tolerated treatment contributes to the burden of chronic HCV. Treatments have improved over time -direct-acting antivirals (DAAs) that targeted different hepatitis C virus genomic sites have shown to be more effective and welltolerated. Patients recover to a greater extent following a treatment regimen based on DAAs. We conducted this literature review to investigate the effectiveness of these medications in treating chronic HCV infection. Relevant articles were identified by searching PubMed and Google scholar databases. Our primary goal was to analyze the efficacy and safety of the DAA, sofosbuvir plus velpatasvir, with or without ribavirin, in cirrhotic or non-cirrhotic, naïve or previously treated, chronic HCV patients. We found that treating patients with sofosbuvir-velpatasvir for 12 weeks was highly effective with fewer adverse events, including those with compensated cirrhosis. The outcomes aided in improving HCV treatment, lowering the disease's burden and fatality rate.

Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea

“…Remarkably, most of the non-responders had high FIB-4 scores, relatively low PLT count (thrombocytopenia can be a surrogate marker of portal hypertension), and high ALT and AST (see “ Supplementary data ” page 1). Many of these findings align with previous literature which suggested that decompensated liver cirrhosis (CTP B and C), and elevated transaminase levels, among others, are associated with lower SVR 31 , 32 . Interestingly, post-treatment AST, ALT, FIB-4 score, and APRI score were significantly lower in a sub-set of patients.…”

Antivirales de acción directa contra la hepatitis C: revisión narrativa

“…El velpatasvir se encuentra en combinación con sofosbuvir (VEL/SOF) con o sin RBV con tasas de RVS mayores al 97 % en todos los genotipos [42]. Además, está combinado con sofosbuvir y voxilaprevir (VEL/ SOF/VOX), y fue aprobado en el 2017 para tratar cualquier genotipo del VHC en pacientes crónicos que previamente no alcanzaron la RVS con el régimen anterior [43].…”